The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.
Transthyretin amyloidosis is considered to be the most common cause of cardiac amyloidosis, with an increasing diagnosis rate over the last decade. Though once considered to be a rare disease, recent data suggest it is underappreciated as a common cause of cardiac diseases and syndromes such as left ventricular hypertrophy, aortic stenosis, and heart failure with preserved ejection fraction, especially in the elderly. Wild-type transthyretin amyloidosis, which is associated with ageing, is currently considered to be the most frequent form of amyloidosis worldwide, and is dominated by cardiac symptoms. Other than male gender and advanced age, risk factors for the development of wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) are largely unknown. There is rising empirical observation that patients with wtATTR-CM frequently have a substantial history of athletic activity, which might contribute to the manifestation of the disease. This study aims to create evidence of a correlation between increased lifetime physical activity and the development of wtATTR-CM. Furthermore, the investigators aim to explore the association between certain sport disciplines and disease development.
Study Type
OBSERVATIONAL
Enrollment
189
* International Physical Activity Questionnaire (IPAQ-SF) * interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form
Medical University of Graz
Graz, Austria
RECRUITINGAssociation between lifetime physical activity (in METs) and disease development
Association between lifetime physical activity (in METs per active decade) and the development of wild-type transthyretin amyloid cardiomyopathy
Time frame: 3rd to 6th decade
Association between lifetime athletic activity (in METs) and disease development
Association between lifetime athletic activity (in METs per active decade) and the development of wild-type transthyretin amyloid cardiomyopathy
Time frame: 3rd to 6th decade
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.